Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1245.50
-24.30 (-1.91%)
< Home < Back

Dr. Reddy’s receives EIR from USFDA for Vishakhapatnam facility

Date: 21-11-2017

Dr. Reddy’s Laboratories has received the Establishment Inspection Report (EIR) from the US Food & Drug Administration (USFDA) for its Formulations Manufacturing Facility at Vishakhapatnam. The USFDA has explained that the inspection has not closed, and the site’s status remains unchanged, but that USFDA has released the EIR in order to be transparent about its regulatory process. The company is planning to request a re-inspection in 2018 after further discussion on scheduling with USFDA.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.